The difference between IgM and IgG antibody prevalence in different serological assays for COVID-19; lessons from the examination of healthcare workers

Kobashi, Yurie; Shimazu, Yuzo; Nishikawa, Yoshitaka; Kawamura, Takeshi; Kodama, Tatsuhiko; Obara, Daiji; Tsubokura, Masaharu

doi:10.1016/j.intimp.2020.107360

Cited by 23 publications

(23 citation statements)

References 12 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The age and sex distributions of the participants are shown in Fig 1C , and the sample characteristics and information on adverse vaccine events stratified by age are provided in Extended Data Table 1 . A portion of this cohort was described previously for the time period extending to 6 months after the first dose of mRNA vaccine 23, 24 .…”

Section: Resultsmentioning

confidence: 99%

Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan

Nakamura

Kobashi

Kim

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Recent studies have provided insights into the effect of vaccine boosters on recall immunity. Given the limited global supply of COVID-19 vaccines, identifying vulnerable populations with lower sustained vaccine-elicited antibody titers is important for targeting individuals for booster vaccinations. Here we investigated longitudinal data in a cohort of 2,526 people in Fukushima, Japan, from April 2021 to December 2021. Antibody titers following two doses of a COVID-19 vaccine were repeatedly monitored and information on lifestyle habits, comorbidities, adverse reactions, and medication use was collected. Using mathematical modeling and machine learning, we stratified the time-course patterns of antibody titers and identified vulnerable populations with low sustained antibody titers. Moreover, we showed that only 5.7% of the participants in our cohort were part of the "durable" population with high sustained antibody titers, which suggests that this durable population might be overlooked in small cohorts. We also found large variation in antibody waning within our cohort. There is a potential usefulness of our approach for identifying the neglected vulnerable population.

show abstract

Section: Resultsmentioning

confidence: 99%

Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan

Nakamura

Kobashi

Kim

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…a standard follow-up for subjects who test IgM positive which currently is to perform real-time reverse transcriptase polymerase chain reaction (RT–PCR) testing. It is vital to evaluate sensitivity of subclinical infections with sera from asymptomatic RT-PCR-positive individuals as positive control, and to assess specificity with sera collected before COVID-19 as negative control [ 97 ]. A study demonstrated that anti-SARS-CoV-2 S-RBD IgG CLIA has outstanding linearity for range of values within and above the cut-off points, rendering it especially useful for vaccinated individuals where antibody values are above the detection limit [ 98 ].…”

Section: Serological Tests Of Antibodiesmentioning

confidence: 99%

Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice

et al. 2021

View full text Add to dashboard Cite

SARS-CoV-2 is a newly identified member of the coronavirus family that has caused the Coronavirus disease 2019 (COVID-19) pandemic. This rapidly evolving and unrelenting SARS-CoV-2 has disrupted the lives and livelihoods of millions worldwide. As of 23 August 2021, a total of 211,373,303 COVID-19 cases have been confirmed globally with a death toll of 4,424,341. A strong understanding of the infection pathway of SARS-CoV-2, and how our immune system responds to the virus is highly pertinent for guiding the development and improvement of effective treatments. In this review, we discuss the current understanding of neutralising antibodies (NAbs) and their implications in clinical practice. The aspects include the pathophysiology of the immune response, particularly humoral adaptive immunity and the roles of NAbs from B cells in infection clearance. We summarise the onset and persistence of IgA, IgM and IgG antibodies, and we explore their roles in neutralising SARS-CoV-2, their persistence in convalescent individuals, and in reinfection. Furthermore, we also review the applications of neutralising antibodies in the clinical setting—from predictors of disease severity to serological testing to vaccinations, and finally in therapeutics such as convalescent plasma infusion.

show abstract

“…In Fukushima Prefecture, 5.1% of the total population completed the third dose as of February 3, 2022 [13]. In addition, certain disaster-affected populations in Fukushima have been continuously subjected to COVID-19 antibody titers monitoring to develop infection prevention measures accordingly [14,15]. This area has an advantage in that the residents are aware of the level of their own liquid immunity after vaccination and how it has evolved, allowing assessment on how this affects their third vaccination behavior.…”

Section: Introductionmentioning

confidence: 99%

Factors Associated with COVID-19 Vaccine Booster Hesitancy: a Retrospective Cohort Study, Fukushima Vaccination Community Survey

Yoshida¹,

Kobashi²,

Kawamura³

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

This was a retrospective cohort study, which aimed to investigate the factors associated with hesitancy to receive the third dose of coronavirus disease 2019 (COVID-19) vaccine. A paper-based questionnaire survey was administered to all participants. Accordingly, the study included participants who provided answer in the questionnaire whether they have an intent to receive the third dose of vaccine. Data on sex, age, area of residence, adverse reactions after the second vaccination, whether the third vaccination was desired, and reasons to accept or hesitate booster vaccination were retrieved. Among the 2439 participants with mean (±SD) age of 52.6±18.9 years, and median IgG-S antibody titer of 324.9 (AU/mL), 97.9% of participants indicated their intent to accept a third vaccination dose. The logistic regression revealed that younger age (OR=0.98; 95% CI: 0.96-1.00) and higher antibody level (OR=2.52; 95% CI: 1.27-4.99) are positively associated with the third vaccine hesitancy. The efficacy of the COVID-19 vaccine and concerns about adverse reactions had significant impact on the third vaccination behavior. A rapid increase in the booster dose rate is needed to control the pandemic, and specific approaches should be taken in these groups that are likely to hesitate the third vaccine, subsequently increasing booster contact rate.

show abstract

The difference between IgM and IgG antibody prevalence in different serological assays for COVID-19; lessons from the examination of healthcare workers

Cited by 23 publications

References 12 publications

Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan

Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan

Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice

Factors Associated with COVID-19 Vaccine Booster Hesitancy: a Retrospective Cohort Study, Fukushima Vaccination Community Survey

Contact Info

Product

Resources

About